Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-7 Mln
ROE
-1.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.2
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
4,271,760
CFO
$-129.51 Mln
EBITDA
$-139.68 Mln
Net Profit
$-179.54 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Histogen (HSTO)
| -2.5 | -2.5 | -91.0 | -92.7 | -81.7 | -79.7 | -65.8 |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
Histogen (HSTO)
| -62.7 | -56.5 | -81.1 | -76.9 | -62.4 | -12.3 |
|
S&P Small-Cap 600
| 13.9 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Histogen (HSTO)
|
0.0 | 0.1 | 0.0 | -12.4 | -65,168.4 | -147.7 | -- | 0.0 |
| 0.0 | 0.0 | 0.0 | -31.6 | -- | -- | -- | 2.3 | |
| 1.9 | 20.3 | 0.0 | -27.7 | -640,975.0 | -240.9 | -- | 1.3 | |
| 135.3 | 28,613.9 | 0.0 | -1,131.3 | -- | -58.1 | -- | 17.5 |
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product... candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California. Read more
President, CEO, CFO, COO, Chief Compliance Officer & Corporate Secretary
Ms. Susan A. Knudson
President, CEO, CFO, COO, Chief Compliance Officer & Corporate Secretary
Ms. Susan A. Knudson
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Histogen Inc (HSTO) is $0.03 (NASDAQ) as of 28-Jan-2025 09:30 EDT. Histogen Inc (HSTO) has given a return of -81.66% in the last 3 years.
Since, TTM earnings of Histogen Inc (HSTO) is negative, P/E ratio is not available.
The P/B ratio of Histogen Inc (HSTO) is 0.02 times as on 28-Jan-2025, a 100 discount to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Histogen Inc (HSTO) are Rs -- and Rs -- as of 27-Apr-2026.
Histogen Inc (HSTO) has a market capitalisation of $ 0 Mln as on 28-Jan-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Histogen Inc (HSTO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.